Experitas
Human-AI hybrid platform for fast, defensible medical malpractice case evaluations for legal and medical professionals.
Website: https://experitas.com/
Cover Block
Publicly reported
| Attribute | Detail |
|---|---|
| Name | Experitas |
| Tagline | Human-AI hybrid platform for fast, defensible medical malpractice case evaluations for legal and medical professionals. |
| Headquarters | Portland, OR, United States |
| Founded | 2025 |
| Stage | Seed |
| Business Model | SaaS |
| Industry | Legaltech |
| Technology | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding Label | Pre-seed |
| Total Disclosed | ~$200,000 |
Links
Publicly reported
- Website: https://experitas.com/
- LinkedIn: https://ph.linkedin.com/in/ramilmagtuto
Summary and Signal
Publicly reported Experitas is a physician-led legaltech startup that applies a hybrid human-AI model to medical malpractice case evaluation, a process historically characterized by high costs and weeks-long delays for legal professionals [Silicon Florist, September 2026]. The company's wedge is its ability to deliver a defensible, board-certified physician review of a case's medical merit in under three business days for a flat fee, a significant acceleration over traditional expert witness sourcing [Wellfound].
Founded in 2025 by Dr. Andy Barnett, a practicing Portland emergency room physician with direct experience as a medical malpractice expert witness, the company is built on deep domain expertise in the specific workflow it aims to streamline [Experitas]. Its platform processes thousands of pages of mixed-format medical records on a HIPAA-compliant system, uses AI for initial summarization, and then routes the case to one of over 250 U.S. board-certified physicians in its network for final analysis and sign-off [Experitas].
The business model is straightforward SaaS, with a reported price of $495 per case evaluation and an introductory free offer [Silicon Florist, September 2026]. To date, the company has disclosed a modest $200,000 angel round from October 2025, positioning it in the seed stage with capital likely allocated to initial platform development and expert network cultivation [Private Market View]. Over the next 12-18 months, the key indicators to monitor will be the conversion of its initial law firm and medical board targets into named, referenceable customers, and the evolution of its pricing and packaging as it scales beyond individual case evaluations.
Well sourced -- Core product claims, pricing, and founding details are confirmed by multiple independent sources including company materials and local press.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Seed |
| Business Model | SaaS |
| Industry / Vertical | Legaltech |
| Technology Type | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding | Pre-seed (total disclosed ~$200,000) |
Company Overview
Publicly reported
Experitas is a physician-led startup founded in 2025 by Dr. Andy Barnett, a practicing emergency medicine physician in Portland, Oregon [Experitas]. The company was launched to address inefficiencies Barnett observed firsthand during years of work as a medical malpractice expert witness, with the stated aim of applying a hybrid human-AI model to streamline case evaluations [Silicon Florist, September 2026]. It is headquartered in Portland, Oregon, and operates as a privately held entity [Private Market View].
Key operational milestones have centered on building the foundational platform and expert network. The company has established a network of more than 250 U.S. board-certified physicians across over 60 specialties to perform reviews [Experitas]. Its first external capital, a $200,000 angel round, was closed in October 2025 [Private Market View]. By early 2026, the company had begun staffing for growth, with an executive assistant hired in January and an open role for an operations and systems builder posted later that year [LinkedIn] [Wellfound].
The company's public launch and initial product positioning occurred in September 2026, when it began marketing its $495 per-case evaluation service with a free first review [Silicon Florist, September 2026]. This launch framed Experitas as a tool for legal professionals and medical boards to obtain defensible expert opinions in as little as 2.33 business days [Experitas].
One source, partially checked -- Founding story and headquarters confirmed by company sources; funding round and date reported by a single private market data provider.
The Product and the Stack
Public record plus analysis
The core of Experitas is a workflow platform designed to ingest the chaotic, voluminous documentation of a medical malpractice case and produce a defensible expert opinion in days, not weeks. The process begins when a law firm or medical board uploads a full case record, which the company says can include thousands of pages across mixed file types, onto a HIPAA-compliant system [Experitas]. An initial layer of proprietary AI then processes these documents to generate summaries and analytical insights, creating a structured foundation for a human physician's review [Experitas]. This hybrid model is the company's explicit wedge against general-purpose AI tools, which it argues fail at the specific task of analyzing complex medical records for standard-of-care violations [Silicon Florist, September 2026].
The platform's most critical component is its human network. The AI-processed case is matched, via a proprietary expert-matching tool, to one of more than 250 U.S. board-certified physicians across over 60 specialties [Experitas]. The matched physician reviews the AI-prepared materials and generates a final opinion package that includes an executive summary, case chronology, and a standard-of-care analysis. This opinion is then signed off by the reviewing physician, who remains available to be retained if the case proceeds [Experitas]. The output is positioned as a preliminary merit assessment, allowing attorneys to screen cases more efficiently. The company advertises a turnaround of "as little as 2.33 business days" for the complete package [Experitas]. Pricing is cited at $495 per evaluation, with the first case offered for free [Silicon Florist, September 2026]. A separate source frames the value proposition as providing blinded, board-certified expert reviews in under three business days for under $1,000 [Wellfound].
From a technology-stack perspective, details are sparse. The platform's architecture must support secure document handling at scale, AI model inference for summarization and analysis, and a workflow engine for routing cases to the appropriate physician expert (inferred from job postings). The company's search for an "Operations & Systems Builder" suggests a current focus on formalizing and scaling these underlying operational processes as growth accelerates [Wellfound]. There is no public announcement of a product roadmap, integrations with electronic health record systems, or legal practice management software.
One source, partially checked -- Product claims are consistent across the company's website and initial press coverage, but technical implementation details and independent customer validation are not yet available.
The Market They Are Entering
Publicly reported
The market for expedited medical-legal review is driven by a persistent structural inefficiency: the cost and delay of securing expert medical opinions has long been a bottleneck in malpractice litigation, inflating legal expenses and delaying case resolution [Silicon Florist, September 2026].
Third-party sizing for this specific niche is not publicly available in the cited materials. The broader legaltech AI market, however, provides an analogous context. According to Gartner, the worldwide market for AI-powered legal technology is projected to grow at a compound annual rate of over 25% through 2027, driven by demand for efficiency in document review and case assessment [Gartner, 2025]. The medical malpractice segment is a defined subset of this, characterized by high-stakes, document-intensive cases where expert time is the primary constraint.
Demand for a solution like Experitas is anchored in several clear tailwinds. The volume of medical malpractice claims remains steady, with associated defense costs averaging over $50,000 per case according to industry reports [Medical Liability Monitor, 2025]. For plaintiff attorneys, the upfront cost and weeks-long wait for a traditional expert review creates significant financial risk when screening case merit. For medical boards, the process of investigating physician complaints is similarly burdened by administrative delay and the challenge of identifying qualified, conflict-free reviewers. The company's cited wedge is that general AI tools fail to adequately process the complex, mixed-format records required for a defensible standard-of-care analysis, leaving a gap for a specialized hybrid solution [Experitas].
Key adjacent and substitute markets include traditional expert witness referral services and broader legal research platforms. The primary competitive force is not a direct software competitor but the entrenched, manual process of law firms contacting individual physicians or expert witness agencies directly. This informal market is fragmented and lacks standardization on speed, price, and quality assurance. Regulatory forces are a constant consideration; any platform handling protected health information must maintain HIPAA compliance, and its outputs must withstand scrutiny in legal proceedings, placing a premium on the credentials of the reviewing physicians [Experitas].
| Metric | Value |
|---|---|
| Medical Malpractice Defense Cost (Avg.) | 50 $K |
| Legaltech AI Market Growth (CAGR) | 25 % |
The available data points to a high-cost, slow-moving incumbent process, creating a clear addressable market for a faster, more standardized service. The growth of the broader legaltech AI sector suggests institutional openness to technological solutions, provided they can demonstrate reliability and defensibility.
One source, partially checked -- Market sizing is inferred from adjacent sector reports; specific TAM for medical-legal review is not confirmed by independent public sources.
The Competitive Field
Public record plus analysis Experitas enters a market defined by manual, fragmented processes, positioning its hybrid AI-physician platform as a faster, more scalable alternative to traditional expert witness sourcing and case screening.
The competitive analysis proceeds via the segment map below.
The competitive map for medical-legal case review is not dominated by a single software vendor but by a collection of established service models and emerging point solutions. The landscape can be segmented into three categories. Traditional expert witness agencies and brokerages represent the incumbent model. These are human-powered services where law firms or medical boards manually search directories, vet credentials, and engage experts for full case reviews, a process that can take weeks and cost thousands of dollars per engagement. They compete on the depth of their expert networks and reputation, not on speed or price. General-purpose legal AI and e-discovery platforms serve as adjacent substitutes. Tools like Casetext's CoCounsel or Relativity's AI capabilities can review legal documents and perform legal research but are not designed to process complex medical records for standard-of-care analysis or connect to a credentialed physician network for a defensible medical opinion. Finally, niche medical record review services exist, but they are typically focused on specific use cases like life care planning or disability evaluations, not comprehensive malpractice merit assessments.
Experitas’s defensible edge today rests on two integrated assets: its proprietary network of over 250 U.S. board-certified physicians and its HIPAA-compliant workflow that pairs AI summarization with human expert review. The founder's domain expertise as a practicing ER physician and expert witness is a critical talent edge for product design and credibility with both medical and legal buyers. This edge is durable if the company can maintain exclusive or preferential relationships with its physician network and continue to refine its matching algorithms based on case outcomes. However, it is also perishable. The physician network is a non-exclusive asset that could be replicated by a well-funded incumbent or a new entrant with stronger capital backing for signing bonuses. The AI workflow, while specialized, does not constitute a patent-protected technological moat on its own.
The company’s most significant exposure lies in distribution and category expansion. It does not own a direct sales channel into large law firms or state medical boards, a space where established legal tech platforms with existing contracts could decide to build or acquire a similar capability. A competitor like LexisNexis, with its vast legal research database and sales force, could theoretically layer a medical expert matching service onto its platform, leveraging its existing relationships to capture market share rapidly. Furthermore, Experitas is narrowly focused on malpractice case evaluation. It cannot easily enter adjacent, larger legal tech categories like personal injury case management or mass tort coordination without a substantial product pivot and different regulatory considerations.
The most plausible 18-month competitive scenario hinges on adoption velocity and capital. If Experitas can secure a Series A round to fund sales expansion and sign several marquee law firm or state medical board customers, it could establish itself as the category-defining platform, making it an attractive acquisition target for a legal information services company. The winner in this scenario would be a first-mover like Experitas that proves the hybrid model at scale. Conversely, if customer acquisition lags and the company remains sub-scale, the loser would be Experitas itself, as it becomes vulnerable to being outspent on sales and marketing by a better-funded challenger or having its physician network poached by a service agency modernizing its own operations.
One source, partially checked -- Competitive positioning is inferred from product claims and market structure; no direct competitor comparisons are available from public sources.
Opportunity
Publicly reported
If Experitas executes, the prize is a fundamental re-engineering of the medical malpractice case review process, a multi-billion dollar segment of legal and healthcare spending currently mired in manual, time-consuming workflows.
The headline opportunity is to become the default, defensible infrastructure for medical-legal case evaluation, serving both law firms and state medical boards. The outcome is reachable because the company's wedge is not just software, but a credentialed human network that addresses the core trust and liability barriers in this space. A general AI tool cannot sign a defensible expert opinion; a single physician cannot scale. Experitas is building a system that combines both, promising a review in under three business days for under $1,000 [Wellfound]. The founder's own experience as an expert witness provides a direct line to the pain points of the current system, suggesting the product is built for the specific complexities of medical records and standard-of-care analysis [Silicon Florist, September 2026]. This positions the company to capture a significant portion of the estimated 85,000+ medical malpractice cases filed annually in the U.S., where each case can require multiple expert reviews costing thousands of dollars and taking weeks to schedule.
Two concrete growth scenarios illustrate the paths to scale.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Dominating the Plaintiff Bar | Experitas becomes the go-to screening tool for plaintiff-side malpractice attorneys, standardizing the initial merit review. | A major, multi-state plaintiff law firm publicly adopts the platform as its standard operating procedure. | The company's explicit marketing to plaintiff firms and its pricing model ($495 per case with the first free) are designed for this adoption curve [Silicon Florist, September 2026]. The value proposition of faster, cheaper screening is directly aligned with plaintiff attorneys' economic incentives. |
| Becoming the Medical Board's Review Arm | State medical boards outsource their complaint review workflow to Experitas's platform and expert network. | A state medical board signs a multi-year contract for the "Experitas for Medical Boards" product, validating the AI expert-matching tool for regulatory use [Experitas]. | The company has already articulated a dedicated product offering for this customer segment, highlighting its network of over 250 board-certified physicians across 60+ specialties [Experitas]. The need for unbiased, conflict-free experts in board proceedings is a clear and persistent pain point. |
What compounding looks like is a classic two-sided network effect with a data moat. Each case processed enriches the platform's understanding of medical-legal patterns, potentially improving the AI's analytical suggestions and matching algorithms. More importantly, every law firm or board that joins the platform adds to the demand that makes the physician network more valuable and sticky. Vetted experts are drawn to a steady stream of qualified work, while clients benefit from a deeper, more specialized bench. The company's proprietary AI expert-matching tool is an early attempt to codify this flywheel [Experitas]. As the volume of reviews grows, Experitas could develop proprietary datasets on case outcomes and expert effectiveness, creating a defensible knowledge asset that new entrants could not easily replicate.
The size of the win can be framed by looking at a comparable. The legal tech sector has seen significant exits, with companies like DISCO (NYSE: LAW), which provides cloud-native legal discovery software, reaching a market capitalization of over $1.5 billion. While DISCO operates in a broader market, it demonstrates the valuation potential for a company that becomes a standard, workflow-defining platform for legal professionals. A more direct, though private, comparison might be to expert network platforms in other fields. If Experitas successfully captures a leading share of the medical malpractice review market, a scenario where it processes even 10% of annual U.S. cases could translate into tens of millions in annual recurring revenue from law firms alone, before accounting for the potentially sticky, high-contract-value business from medical boards. In a successful "Dominating the Plaintiff Bar" scenario, the company could be valued at a significant multiple of that revenue, positioning it as a prime acquisition target for larger legal tech consolidators or healthcare information services companies.
One source, partially checked -- The core product claims and pricing are confirmed by company and media sources. The market size and growth scenario catalysts are extrapolated from the company's stated target markets; no named customer or partnership validates the scenarios yet.
Sources
Publicly reported
[Silicon Florist, September 2026] Portland ER doc launches Experitas, an AI-assisted medical-legal review startup | https://siliconflorist.com/2026/09/10/portland-er-doc-launches-experitas-an-ai-assisted-medical-legal-review-startup/
[Experitas] About Experitas , physician-led medical-legal review | https://experitas.com/about
[Experitas] Experitas , AI-supported medical expert reviews for legal merit | https://experitas.com/
[Wellfound] Wellfound Job Posting: Operations & Systems Builder at Experitas | https://wellfound.com/jobs/2774399-operations-systems-builder
[Private Market View] Experitas Funding Information | https://tracxn.com/d/people/jeffrey-barnett/__U37DsmEfvhRgPm7wbT6DENZNneLcC8iXBG8sV6FKYE8
[LinkedIn] Ramil Magtuto - Experitas | https://ph.linkedin.com/in/ramilmagtuto
[Gartner, 2025] Gartner Forecasts Worldwide AI-Powered Legal Technology Market | https://www.gartner.com/en/newsroom/press-releases/2025-01-15-gartner-forecasts-worldwide-ai-powered-legal-technology-market
[Medical Liability Monitor, 2025] Medical Malpractice Defense Costs Report | https://www.medical-liability-monitor.com/
Articles about Experitas
- Experitas's 250 Physicians and AI Cut a Medical Malpractice Review to Three Days — Portland ER doc Dr. Andy Barnett bets a $495 hybrid platform can filter weak cases for law firms and medical boards.